Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux and NuGen Ink Cross-License Agreement for Amplification Technologies

This article has been updated from a previous version, which incorrectly stated that BioMérieux acquired exclusive rights to NuGen's amplification system. 
 
NEW YORK (GenomeWeb News) - BioMérieux and NuGen Technologies have signed a cross-license and supply agreement to share amplification technologies for expression analysis, the companies said today.
 
The agreement gives BioMérieux non-exclusive rights to NuGen’s WT-Ovation RNA amplification system, and grants NuGen access to BioMérieux’s linear amplification technology.
 
BioMérieux will use NuGen’s technology to develop microarray-based cancer assays, while NuGen gains original equipment manufacturer rights to BioMérieux’s linear amplification technologies for the research market.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.